SEATTLE, WA / ACCESSWIRE / June 30, 2021 / EMulate Therapeutics Inc., a clinical-stage therapeutic device company, announced today that management will participate in an Access to Giving Virtual Investor Conference July 13th – 15th, 2021
Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About Access to Giving Conference
Access to Giving is a first-of-its-kind virtual investor conference where companies from microcap all the way up to megacap will have the opportunity to present their story in 1×1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies. https://www.accesstogiving.com/
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical-stage therapeutic device company that makes targeted, non-invasive, safe, and effective treatment a reality. The company’s groundbreaking technology has the potential to treat cancer and various other diseases without chemicals, radiation, or drugs and with minimal or no adverse effects. The technology is based on magnetically-induced changes to cellular function to produce a therapeutic response. It uses precisely targeted, ultra-low radiofrequency energy delivered via non-invasive devices, such as the EMulate Therapeutics Voyager and Hӕlo®, to specifically regulate signaling and metabolic pathways on the molecular and genetic levels. To learn more, please visit https://emulatetx.com/
Investor Contact
James Carbonara
Hayden IR
Tel (646) 755-7412
james@haydenir.com
SOURCE: EMulate Therapeutics Inc.
View source version on accesswire.com:
https://www.accesswire.com/652270/EMulate-Therapeutics-to-Participate-in-Access-to-Giving-Virtual-Investor-Conference-July-13th–15th-2021
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…
- Attruby is the first and only approved product with aspecifying near-complete stabilization…
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape -…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…